Metabolic Extraction of Nifedipine during Absorption from the Rat Small Intestine

doi:10.2133/dmpk.17.546

Drug Metabolism and Pharmacokinetics

Volume 17, Issue 6, 2002, Pages 546-553

https://doi.org/10.2133/dmpk.17.546 Get rights and content

Summary:

Nifedipine is one of drugs that have been suggested to undergo significant first-pass metabolism by cytochrome P450 (CYP) 3A in the intestine, based mainly on pharmacokinetic analyses of in vivo observations. To further substantiate this suggestion, we examined the metabolic extraction of nifedipine from the rat small intestine, using intestine perfused in situ by a single-pass technique and microsomes in vitro. When the intestinal lumen was perfused with nifedipine solution (30 μM) at the flow rate of 0.15 mL/min and steady-state was achieved, the fraction that disappeared from the intestinal lumen (F_a) and the fraction absorbed into the mesenteric venous blood (F_a,_b) was 0.26 and 0.13, respectively. Thus, F_a,_b was 50% smaller than F_a, indicating a significant extraction of nifedipine during passage through the intestinal mucosa. When ketoconazole (40 μM), a specific inhibitor of CYP3A, was added to the perfusion solution, F_a,_b was increased to a level comparable with F_a, while F_a remained unchanged, suggesting the complete inhibition of metabolic extraction by CYP3A. A similar result was obtained for cyclosporin A (40 μM), another specific CYP3A inhibitor. In intestinal microsomes, the metabolic degradation of nifedipine (1 μM) was almost completely inhibited by ketoconazole (10 μM) and cyclosporin A (10 μM), consistent with the results in the perfused intestine. It was also found in intestinal microsomes that anti-rat CYP3A2 antibody can inhibit nifedipine metabolism completely. Thus, the present study demonstrates that nifedipine undergoes significant extraction during passage through the intestinal mucosa, and provides substantial evidence that CYP3A2 is responsible for that.

References (36)

D.G. Bailey et al.
Interaction of citrus juices with felodipine and nifedipine
Lancet
(1991)
H. Yuasa et al.
Determination of kinetic parameters of a carrier-mediated transport in the perfused intestine by two-dimensional laminar flow model: effect of the unstirred water layer
Biochim. Biophys. Acta
(1986)
V. Horvath et al.
Sensitive high-performance liquid chromatographic determination of nifedipine in dog plasma using an automated sample preparation system with laboratory robot
J. Chromatogr. B.
(1996)
H. Yuasa et al.
Comparative assessment of the resistance of the unstirred water layer to solute transport between two different intestinal perfusion systems
Biochim. Biophys. Acta
(1988)
S. Imaoka et al.
Multiple forms of human P450 expressed in Saccharomyces cerevisiae
Biochem. Pharmacol.
(1996)
F.P. Guengerich et al.
Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
J. Biol. Chem.
(1986)
G.V. Gushchin et al.
A novel cytochrome P450 3A isoenzyme in rat intestinal microsomes
Biochem. Biophys. Res. Commun.
(1999)
J.H. Lin et al.
Is the role of the small intestine in first-pass metabolism overemphasized?
Pharmacol. Revs.
(1999)
G.K. Dresser et al.
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
Clin. Pharmacokinet.
(2000)
Μ.Μ. Doherty et al.
The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?
Clin. Pharmacokinet.
(2002)

D.G. Bailey et al.

Grapefruit juice and drugs: how significant is the interaction?

Clin. Pharmacokinet.

(1994)

T.J. Rashid et al.

Factors affecting the absolute bioavailability of nifedipine

Br. J. Clin. Pharmacol.

(1995)

R.D. Krishna et al.

Extrahepatic metabolism of drugs in humans

Clin. Pharmacokinet.

(1994)

Μ.F. Paine et al.

Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism

J. Pharmacol. Exp. Ther.

(1997)

Q.Y. Zhang et al.

Characterization of human small intestinal cytochromes P-450

Drug Metab. Dispos.

(1999)

M.A. Gibbs et al.

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of K_i values and impact of CYP3A5 expression

Drug Metab. Dispos.

(1999)

R.S. Obach et al.

Metabolic characterization of the major human small intestinal cytochromes P-450 s

Drug Metab. Dispos.

(2001)

C.H. Kleinbloesem et al.

Nifedipine: kinetics and dynamics in healthy subjects

Clin. Pharmacol. Ther.

(1984)

Cited by (25)

Exploring the potential impact of probiotic use on drug metabolism and efficacy
2023, Biomedicine and Pharmacotherapy
Probiotics are frequently consumed as functional food and widely used as dietary supplements, but are also recommended in treating or preventing various gastrointestinal diseases. Therefore, their co-administration with other drugs is sometimes unavoidable or even compulsory. Recent technological developments in the pharmaceutical industry permitted the development of novel drug-delivery systems for probiotics, allowing their addition to the therapy of severely ill patients. Literature data regarding the changes that probiotics could impose on the efficacy or safety of chronic medication is scarce. In this context, the present paper aims to review probiotics currently recommended by the international medical community, to evaluate the relationship between gut microbiota and various pathologies with high impact worldwide and, most importantly, to assess the literature reports concerning the ability of probiotics to influence the pharmacokinetics/pharmacodynamics of some widely used drugs, especially for those with narrow therapeutic indexes. A better understanding of the potential influence of probiotics on drug metabolism, efficacy and safety could contribute to improving therapy management, facilitating individualized therapy and updating treatment guidelines.
Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism
2010, Journal of Pharmaceutical Sciences
Citation Excerpt :
The common array of in vitro, in situ, and in vivo ADME and PK/PD models are as diverse in their advantages as they are in their limitations and most often, a combination of techniques and model systems is considered the most reliable experimental approach. The in situ perfused rat intestine has been employed to investigate mechanisms of drug absorption of a wide range of molecules including but not limited to angiotensin II receptor antagonists,3 digoxin,4 nifedipine,5 verapamil,6 diltiazem,7 quinidine,8 and insulin.9 Intestinal perfusion is a low throughput experimental method but can provide reliable mechanistic information on physical and biological barriers that limit intestinal drug absorption.
The absorption of drug molecules is often investigated using in vitro or in situ models of the intestinal mucosa; however, few studies have quantified the kinetics that limit absorption. The objective of this study was to quantify kinetic rates of rat intestinal absorption, metabolism, and efflux using nonlinear mixed effects modeling. A multicompartment model accurately described the absorption and distribution of atenolol and verapamil as well as the metabolism of verapamil and distribution of the metabolite, norverapamil. The accurate description of atenolol data required inclusion of an intermediate compartment in addition to paracellular clearance, whereas verapamil and norverapamil were modeled in the absence of paracellular clearance. The absorption of verapamil was well characterized by linear kinetics, whereas the formation and distribution of norverapamil were well characterized by Michaelis–Menten kinetics. The model identified EDTA as a modulator of physical barriers, ketoconazole as an inhibitor of cytochrome P450 3A and P-glycoprotein (P-gp), and PSC-833 and GF-120918 as specific P-gp inhibitors. These results demonstrate the utility of a physiologically based model to characterize (i) the drug distribution across the in situ perfused rat intestine and (ii) the effect of chemical modulators in this biological system. © 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99:999–1015, 2010
Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. role of metabolic enzymes in the intestinal mucosa
2009, Journal of Pharmaceutical Sciences
Citation Excerpt :
Nifedipine undergoes significant extraction during passage through the intestinal mucosa. Substantial evidence indicates that CYP3A is responsible for the extraction.47 Based on the results described in this manuscript, we have concluded that AOA-DADLE, CA-DADLE, and OMCA-DADLE are very good substrates for CYP 3A that is found in microsomes prepared from rat liver.
The objective of this study was to determine the relative importance of metabolism by cytochrome P450 (CYP) enzymes versus efflux by P-glycoprotein (P-gp) in restricting the intestinal mucosal permeation of cyclic prodrugs (AOA-DADLE, CA-DADLE, OMCA-DADLE) of the opioid peptide DADLE (H-Tyr-d-Ala-Gly-Phe-d-Leu-OH). AOA-DADLE, CA-DADLE, and OMCA-DADLE were shown to be rapidly metabolized by rat liver microsomes and human CYP-3A4 and to a lesser extent by esterases. Using an in situ perfused rat ileum model, ketoconazole, a CYP 3A inhibitor, was shown to have no effect (AOA-DADLE) or a slight enhancing effect (OMCA-DADLE, twofold; CA-DADLE, threefold) on their intestinal mucosal permeation. In contrast, inclusion of PSC-833, a P-gp inhibitor, in the perfusate significantly enhanced (7–16-fold) the permeation of the three cyclic prodrugs. Since PSC-833 was found to be a weak inhibitor of CYP 3A4 and to have no inhibitory effects on esterases, phenol sulfotransferases, and glucuronyltransferases, it is suggested PSC-833 enhances intestinal mucosal permeation of these cyclic prodrugs by inhibiting their polarized efflux and not by inhibiting their metabolism. Furthermore, efflux transporters (e.g., P-gp), not metabolic enzymes (e.g., CYP 3A, esterases), restrict the permeation of peptide prodrugs across the rat intestinal mucosa.
Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates
2008, Journal of Pharmaceutical Sciences
Citation Excerpt :
A review by Bailey et al.20 has indicated that oral pharmacokinetics of nifedipine is altered by an intake of grapefruit juice of which components inhibit small intestinal CYP3A enzymes. Estimated Fa × Fg values were in a similar range in the three species examined (human, rat and dog),14, 99, 121, 122 which is almost consistent with a marginal difference in intestinal metabolic activity between humans and rats.77, 89, 95 It has been demonstrated that based on a single path perfusion method the intestinal availability of nifedipine in the rat is increased in the presence of ketoconazole or cyclosporine.122
Intestinal first‐pass metabolism has a great impact on the bioavailability of CYP3A substrates in humans, and the in vivo impact has quantitatively been evaluated using CYP3A inhibitors or inducers. In vitro and in vivo preclinical investigations for intestinal metabolism are essential in clarifying pharmacokinetic behavior in animal species and predicting the effect of intestinal metabolism in the human. In this review, we will discuss species differences in intestinal CYP3A enzymes, and CYP3A‐mdediated intestinal elimination. Identical CYP3A4 enzyme is expressed in human intestine and liver, but different CYP3A enzymes in both tissues of the mouse and rat are found, that is, respective intestinal enzyme is considered as cyp3a13 and CYP3A62. There is little information on CYP3A enzymes in the monkey and dog intestine, unlike the liver. In vitro metabolic activities of midazolam and nisoldipine are higher in the human and monkey than in the rat. In vivo assessment of cyclosporine, midazolam, nifedipine, tacrolimus, and verapamil has been reported in various species (monkey, rat, mouse, and/or dog) including the human. For midazolam, the monkey shows significant in vivo intestinal metabolism, as evidenced in the human. The monkey might be an appropriate animal model for evaluating small intestinal first‐pass metabolism of CYP3A substrates.
Effect of subacute methyl parathion administration on the pharmacokinetics and pharmacodynamics of nifedipine in rats
2007, Environmental Toxicology and Pharmacology
Citation Excerpt :
The present study is undertaken to determine whether or not subacute MP administration affects the metabolism and pharmacological responses of the calcium channel antagonist nifedipine in rats. Nifedipine is metabolised mainly by CYP3A in rat small intestine and liver (Iwao et al., 2002). Parathion is a prototype thiono-sulfur containing phosphorothioate insecticide in commercial use in many developing countries.
Families living in agricultural areas may submitted to repeated exposure of methyl parathion (MP) that has been widely used as an agricultural insecticide. MP inhibits cytochrome P450 enzymes and has the potential to alter pharmacokinetic profiles of therapeutic agents that are metabolized in the liver. The aim of the present study is to investigate the possibility that the increased pharmacokinetic and pharmacodynamic effects of nifedipine is due to the inhibition of the metabolism after repeated administration of low doses of MP in rats. Male rats received commercial formulation of diluted MP (1/100 LD₅₀ or 1/25 LD₅₀, n = 6) or tap water (control, n = 5) via gastric gavage (0.5 ml) for 14 days. On the 15th day, the carotid artery and jugular vein were cannulated for measurement of cardiovascular parameters and blood sampling, respectively. Nifedipine was administered 3 mg/kg via the cannula inserted in the duodenum of the rat. Subacute MP administration did not change pharmacokinetic AUC_(0–240), C_max, t_max, t_1/2) and pharmacodynamic (mean arterial pressures and heart rates) parameters of nifedipine. These findings provide evidence that repeated exposure of low doses of commercial MP did not affect the elimination of nifedipine which might be due to the lack of inhibition of CYP3A in rats.
Absorption and metabolism of albendazole after intestinal ischemia/reperfusion
2007, European Journal of Pharmaceutical Sciences
Pathophysiological processes involving inflammatory response may affect absorption and biotransformation of some drugs, modifying their pharmacokinetic behaviour. Ischemia/reperfusion (I/R) injury has been used as a model for inflammatory processes. The aim of this work was to study the effect of intestinal I/R injury on the absorption and metabolism processes of one orally administered drug, albendazole that is anthelmintic drug, it undergoes intestinal bioconversion into albendazole sulfoxide by two enzymatic systems, cytochromes P450 (CYP450) and flavin-containing monooxygenase (FMO). Male Wistar rats were used to study the influence of I/R in the intestinal absorption and metabolism of albendazole, after 60 min of mesenteric occlusion and 30 min of reperfusion. The intestinal studies were performed in microsomal, and everted ring incubations. During in situ studies, the I/R group had faster disappearance of albendazole from the lumen. In addition, albendazole only appeared in blood samples of the I/R group, while albendazole sulfoxide appeared in both samples and was higher in the control group. These findings are supported by significant reductions of albendazole sulfoxide formation in intestinal everted ring assays and in microsomal incubations after the I/R process. Both metabolizing systems, CYP4503A and FMO, were affected by I/R. Our data indicate that I/R injury, considered as an inflammatory model, reduces absorption and metabolism processes of albendazole.

View all citing articles on Scopus

View full text

Regular ArticleMetabolic Extraction of Nifedipine during Absorption from the Rat Small Intestine

Summary:

Lancet

Biochim. Biophys. Acta

J. Chromatogr. B.

Biochim. Biophys. Acta

Biochem. Pharmacol.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

Is the role of the small intestine in first-pass metabolism overemphasized?

Pharmacol. Revs.

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

Clin. Pharmacokinet.

The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Clin. Pharmacokinet.

Grapefruit juice and drugs: how significant is the interaction?

Clin. Pharmacokinet.

Factors affecting the absolute bioavailability of nifedipine

Br. J. Clin. Pharmacol.

Extrahepatic metabolism of drugs in humans

Clin. Pharmacokinet.

Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism

J. Pharmacol. Exp. Ther.

Characterization of human small intestinal cytochromes P-450

Drug Metab. Dispos.

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression

Drug Metab. Dispos.

Metabolic characterization of the major human small intestinal cytochromes P-450 s

Drug Metab. Dispos.

Nifedipine: kinetics and dynamics in healthy subjects

Clin. Pharmacol. Ther.

Regular Article
Metabolic Extraction of Nifedipine during Absorption from the Rat Small Intestine

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of K_i values and impact of CYP3A5 expression